Fach- und Laienpublikum
Virtueller Vortrag von Dr. James Rucker, King's College London
After a 30 year pause there has been a slow but steady resurgence of clinical research interest into psilocybin, which is a classical psychedelic (like LSD) and the active component of so-called ‘magic mushrooms’. That this has happened despite the strictest of legal restrictions on use is notable, suggesting a broader sociopolitical shift in attitudes towards previously demonised ‘drugs of abuse'. Dr. Rucker is a consultant psychiatrist at the Maudsley Hospital in London and was recently awarded a large grant from the UK Government (National Institute for Health Research (NIHR)) to investigate the safety, feasibility and efficacy of psilocybin as a treatment for depression. He leads the Psychedelic Trials Group at the Institute of Psychiatry, Psychology & Neuroscience at King’s College London. In this online webinar Dr. Rucker will summarise the history and early medical use of classical psychedelics in Western psychiatry, their fall from grace after 1970 and the early clinical trials now taking place to investigate their safety and efficacy as treatments for forms of depression and anxiety that are otherwise resistant to treatment.
Dr. James Rucker, King's College London
Klinik für Psychiatrie und Psychotherapie
Charité Campus Benjamin Franklin
Mittwoch, 2. Dezember 2020
Der Link zur Videokonferenz wird ein paar Tage vor dem Vortrag hier veröffentlicht.